Wellbeing Digital Sciences Inc. - KONEF STOCK NEWS

KetamineOne Capital Limited announces that its client, Hofseth Biocare ASA, has achieved New Dietary Ingredient (NDI) status from the FDA for its products CalGo® and OmeGo®, derived from Norwegian Atlantic salmon. This recognition places HBC among a select group of companies with successful NDI applications.

This FDA approval supports HBC's innovative extraction technology and enhances their market position. The FDA’s acknowledgment is a significant milestone as only about 30% of NDI notifications receive approval each year.

Ketamine One Capital Limited (KONEF) announces a partnership with Cognetivity Neurosciences to develop assessments for depression and post-traumatic stress disorder (PTSD). Two clinical studies are set to begin in early 2022, utilizing Cognetivity's Integrated Cognitive Assessment (ICA) technology, already deployed in Ketamine One's clinics. This collaboration aims to validate ICA's effectiveness in monitoring cognitive changes during treatment, enhancing Ketamine One's position in the growing mental health market, which is expected to exceed USD 13 billion by 2027.

KetamineOne Capital Limited (KONEF) provided an update regarding a management cease trade order (MCTO) granted on November 1, 2021, by the British Columbia Securities Commission. The order follows a delay in the filing of the company's financial statements for the fiscal year ending July 31, 2021. KetamineOne plans to file the required documents by December 10, 2021, and will continue to issue bi-weekly reports until compliance is achieved. The general public can still trade the company's shares, although its CEO and CFO are prohibited from trading during the MCTO.

KetamineOne Capital Limited has announced that its subsidiary, IRP Health, received ethics approval for an open-label PTSD study linked to its 12-week physical therapy program. The company also opened two veteran-focused clinics in Comox Valley and Ottawa, expanding its reach to first responders and veterans. Over 10,000 treatments have been conducted, highlighting strong demand for these services. The ongoing PTSD study aims to recruit participants soon, offering additional opportunities for veterans lacking funding from Veterans Affairs Canada.

KetamineOne Capital Limited (OTC: KONEF) announced updates regarding a management cease trade order (MCTO) issued by the British Columbia Securities Commission on November 1, 2021. This MCTO is due to a delay in filing the company's annual financial statements for the fiscal year ending July 31, 2021. KetamineOne aims to file these documents by November 29, 2021, and will provide ongoing updates. During the MCTO, key executives cannot trade shares, while the general public can. The company continues to focus on consolidating medical clinics and enhancing mental health treatment accessibility.

KetamineOne Capital Limited announced plans to confidentially submit a draft registration statement for a potential IPO of common shares in the U.S., targeting up to USD 20 million. The offering is expected in the first half of 2022, with specific share counts and use of proceeds yet to be determined. Additionally, Steven Inglefield has been appointed as Chief Operating Officer, bringing over 16 years of experience in health and wellness. The company focuses on consolidating medical clinics and expanding its presence in mental health treatments.

KetamineOne Capital Limited (OTC: KONEF) has announced the resignation of Loreto Grimaldi from its Board of Directors, effective November 3, 2021. Grimaldi served on the board since June 2021, and the company expressed gratitude for his contributions. KetamineOne is focused on consolidating medical clinics and aims to lead in North American mental health treatments, providing essential infrastructure for breakthrough therapies. The company operates a network of clinics and has expanded its contract research division through KGK Science Inc., enhancing its capabilities in clinical research.

KetamineOne Capital Limited (KONEF) announced delays in its annual financial filings due to complexities arising from subsidiary integration and COVID-19 related challenges. A management cease trade order has been granted by the British Columbia Securities Commission, restricting trading by key executives. The Company expects to finalize and submit its annual reports by November 29, 2021. During this period, general public trading can continue, but management is prohibited from trading the company’s shares. KetamineOne aims to consolidate medical clinics and enhance mental health treatments across North America.

Ketamine One Capital Limited has updated its OTC and Frankfurt listings following the spin-out of Milguass Investments Ltd.. As of October 15, 2021, Ketamine One's shares now have a new CUSIP number (492556105) and ISIN number (CA4925561058). The company continues to trade under the KONEF ticker on OTC Markets and has rebranded on the Frankfurt Exchange with the new ticker 6FC. Furthermore, Ketamine One is pursuing 15c2-11 Certification to enhance trading conditions for its shares, which have been previously labeled as Unsolicited-Only.